German Congress of Orthopaedics and Traumatology (DKOU 2025)
Long-term efficacy of the press-fit acetabular cup system Plasmafit: A decade-long prospective study
2Diakonie-Klinikum, Stuttgart, Deutschland
Text
Objectives and questions: The Plasmafit acetabular system was introduced to the market in 2012. Since then, more than 550,000 cups were implanted. The Plasmafit system was designed to provide high primary stability and low-abrasion articulation. The current prospective, multi-centric, non-interventional study is the first study providing long-term data on this frequently used acetabular system.
Material and methods: 100 consecutive patients who underwent Total Hip Arthroplasty (THA) with the Plasmafit acetabular cup system (Aesculap AG) between 06/2012 and 11/2012 at two hospitals were included in the study. Patients were examined 3 months, 1 year, 5 years and 10 years after surgery.
The primary endpoint was revision of the acetabular cup, with all reasons for revision. Revision rates were calculated using the Kaplan-Meier estimator.
Secondary endpoints were clinical (Harris Hip Score (HSS), leg pain according to the Visual Analogue Scale (VAS) at rest and under stress) and radiological outcome.
Results: Patient demographics at time of surgery and primary indications are summarized in Table 1 [Tab. 1].
Table 1: Demographics at time of surgery and primary indications of the Plasmafit study cohort. 
Anterolateral approach was used in 55 patients and lateral approach in 45 patients. In total, 16 different surgeons performed the surgeries.
65 patients completed the 10 years examination. Eight patients died, 16 withdrew their consent and eleven patients were lost to follow-up.
During the course of the study there was one exchange of an acetabular liner due to squeaking and 3 stem revisions due to loosening (n=2) or sintering (n=1). There was no revision of the Plasmafit acetabular cup itself nor any adverse event related to the acetabular cup. Thus, the cumulative survival of the Plasmafit acetabular system was 98.8%.
HHS and pain improved significantly compared to preoperative values. The data is summarized in Table 2 [Tab. 2].
Table 2: HHS and pain development in patients of the Plasmafit study cohort.There were no major radiographic signs indicating loosening of the acetabular cup. 
Discussion and conclusions: The Plasmafit acetabular cup has demonstrated excellent overall survivorship as well as clinical and radiological results with a low rate of complications at a long-term follow-up. The presented data is in accordance with data from international arthroplasty registries (NJR – 10 year survival rate: 98.2%, EPRD – 9 year survival rate: 95.8%).
